Walvax Biotechnology (SHE:300142), through subsidiary Walvax Hong Kong, signed an overseas market cooperation deal with Jiangsu Zhonghui Yuantong Biotechnology, according to a Shenzhen bourse filing on Saturday.
Under the seven-year deal, Zhonghui Yuantong and its affiliates agreed to have Walvax HK as its exclusive partner for the international business development and sales of vaccines in designated regions, except Macau and the Philippines.
The Chinese biotechnology company rose 2% during Monday's midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments